RC
CASI

RBF Capital’s CASI Pharmaceuticals CASI Stock Holding History

RBF Capital’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,936
Closed -$46K – 534
2022
Q2 		$46K Sell
15,936
-1
-0% -$4 ﹤0.01% 515
2022
Q1 		$142K Hold
15,937
– – 0.01% 494
2021
Q4 		$127K Buy
+15,937
New +$159K 0.01% 501

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

RBF Capital's CASI Position: Q3 2022 in Review

RBF Capital sold out of CASI Pharmaceuticals (CASI) in Q3 2022, closing a stake of 15,936 shares — an estimated $46K sold.

RBF Capital first reported a position in CASI in Q4 2021 and held it in 3 quarters. The position peaked at $142K in Q1 2022. 24 funds tracked by Wall St. Rank hold CASI as of Q3 2022.

  • RBF Capital reported no remaining CASI Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • RBF Capital sold 15,936 CASI Pharmaceuticals shares in Q3 2022, an estimated $46K.
  • RBF Capital first reported a position in CASI Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • RBF Capital's CASI Pharmaceuticals position peaked at $142K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2022.

Based on RBF Capital's 13F filing for Q3 2022, filed 14 Nov 2022.